Alsace, Grand Est, France The fund was located in Europe if to be more exact in France. The main office of represented Corporate Investor is situated in the Mulhouse.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the SODIV ALSACE, startups are often financed by Sofinnova Partners, Idinvest Partners, Groupe Siparex. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Auriga Partners, Alsace Business Angels. In the next rounds fund is usually obtained by Seventure Partners, Michael J. Fox Foundation, Financiere De l'Echiquier.
The fund is generally included in less than 2 deals every year. The important activity for fund was in 2012. The usual things for fund are deals in the range of 1 - 5 millions dollars. Speaking about the real fund results, this Corporate Investor is 13 percentage points more often commits exit comparing to other organizations.
We can highlight the next thriving fund investment areas, such as Commercial, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Domain Therapeutics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - France.
Related Funds
| Fund Name | Location |
| Avista Development | Spokane, United States, Washington |
| car2go | Israel, Tel Aviv, Tel Aviv District |
| Fuqua Investments | - |
| GLS Ventures | Sugar Land, Texas, United States |
| Guillemot Corporation | Bretagne, Chantepie, France |
| Huaxin Ziyuan | China, Guangdong, Shenzhen |
| iTo | - |
| Jaguar Land Rover Tech Incubator | Oregon, Portland, United States |
| Liga Ventures | Brazil, São Paulo, Sao Paulo |
| NICE Group | Seoul, Seoul-t'ukpyolsi, South Korea |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Rhenovia Pharma | $637K | 12 Feb 2014 | Grand Est | ||
Firalis | $531K | 30 Jun 2010 | Grand Est |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Rhenovia Pharma | $637K | 12 Feb 2014 | Grand Est | ||
Firalis | $531K | 30 Jun 2010 | Grand Est |
